Quest Diagnostics Appoints Former Walgreens Boots Alliance CEO Timothy Wentworth to Board
DGX sits 28% above its 52-week low of $157.2.
Summary
Quest Diagnostics has appointed Timothy Wentworth, former CEO of Walgreens Boots Alliance and other major healthcare firms, as an independent director, bringing significant industry and leadership experience to the board.
Key Events · Executive and Board Changes · DGX
-
New Independent Director Appointed
Timothy Wentworth, former CEO of Walgreens Boots Alliance, Evernorth Health Services, and Express Scripts, has been elected to the Board of Directors, effective March 9, 2026.
-
Strengthens Board Expertise
Mr. Wentworth brings extensive leadership experience in large, publicly traded healthcare organizations, with expertise in health plan, employer, and consumer channels, enhancing the board's strategic capabilities.
-
Committee Appointments
He will serve on the Board's Compensation and Leadership Development Committee and the Quality and Compliance Committee.
-
Standard Director Compensation
As part of his compensation, Mr. Wentworth received a prorated one-time grant of restricted share units valued at approximately $43,000.
Analysis · DGX · Industrial Applications And Services
The appointment of Timothy Wentworth, a seasoned leader with extensive CEO experience from major healthcare organizations like Walgreens Boots Alliance and Evernorth Health Services, significantly strengthens Quest Diagnostics' Board of Directors. His deep expertise in health plan, employer, and consumer channels, along with operational and HR knowledge, is highly relevant to the company's strategic direction and will enhance governance and oversight.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DGX was trading at $200.88 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $157.20 to $213.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.